Edison healthcare quarterly: How to please some of the people some of the time
![](https://d3s3shtvds09gm.cloudfront.net/9f146db2d533c9c85ec47908fd0c6d92.jpg)
![](https://d3s3shtvds09gm.cloudfront.net/9f146db2d533c9c85ec47908fd0c6d92.jpg)
There’s just no pleasing some people. Take AstraZeneca’s investors, for instance. A $1.3bn acquisition, an innovative risk-sharing deal with the world’s biggest biotech company, Amgen, and the departure of an unpopular CEO – all within the space of four weeks – was still not enough to stem a haemorrhaging share price and prevent over £2bn being wiped off the UK company’s market
cap in a day.